Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q4 2019 Earnings Conference Call February 4, 2020 8:30 AM ET Company Participants Coleman Lannum - Senior Vice President of Investor Relations Bryan Hanson - President and Chief Executive Officer Suketu Upadhyay - Executive Vice President and Chief Financial Officer Keri Mattox - Senior Vice President, Investor Relations and Chief Communications Officer Conference Call Participants Raj Denhoy - Jefferies & Company, Inc. Vijay Kumar - Evercore ISI Matthew Miksic - Cred ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2019 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 345 East Main Street, Warsaw, IN 46580 (Address of princip ...

Start Time: 08:30 January 1, 0000 9:36 AM ET Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q3 2019 Earnings Conference Call November 05, 2019, 08:30 AM ET Company Participants Bryan Hanson - President and CEO Suketu Upadhyay - EVP and CFO Coleman Lannum - SVP, IR Conference Call Participants Larry Keusch - Raymond James Steven Lichtman - Oppenheimer Chris Pasquale - Guggenheim Securities Pito Chickering - Deutsche Bank Kristen Stewart - Barclays Kyle Rose - Canaccord Genuity Josh Jennings - Cowen and Company Jeff ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2019 Commission File Number 001-16407 Delaware 13-4151777 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 345 East Main Street, Warsaw, IN 46580 (Address of principal executive offices) Telephone: (574) 267-6131 Securities registered pursuant to Section ...

Financial Data and Key Metrics Changes - Net sales totaled $2 billion in Q2 2019, a decrease of 0.9% from the prior year period, but an increase of 1.2% on a constant currency basis [35] - GAAP diluted earnings per share for the quarter was $0.65, while non-GAAP adjusted diluted earnings per share were $1.93 [39] - Adjusted operating margin was 27.4% for the quarter, in line with expectations [41] Business Line Data and Key Metrics Changes - The Knee franchise grew 2.5% on a constant currency basis, with solid performance across all geographic regions [38] - The S.E.T. business grew 4.3% on a constant currency basis, while the Dental business grew 1.7% [38] - The company experienced growth deceleration in the Spine & CMF business, with expectations for improvement as new products launch [32] Market Data and Key Metrics Changes - Asia-Pacific region delivered strong performance with 4.7% sales growth, while EMEA increased sales by 1.9% [36] - The Americas region saw a slight increase of 0.1%, reflecting improved performance across most product categories [37] Company Strategy and Development Direction - The company is focused on driving efficiency throughout its supply chain and has rolled out a culture program called "Quality Begins With Me" [22][23] - New product introductions, including the ROSA robotics platform and mymobility digital health platform, are part of the strategy to deliver customer-centric solutions [23] - The company plans to increase investment in robotics and specialized sales channels to enhance growth in high-potential markets [29][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the turnaround progress and updated guidance for 2019, expecting to achieve weighted average market growth rate six months ahead of schedule [33] - The leadership team noted that the organization is more engaged and focused than in previous years, with a strong corporate culture emerging [24] - Management highlighted the importance of maintaining momentum in the Knee franchise and S.E.T. business for future growth [57] Other Important Information - A $70 million one-time non-cash charge was recorded in Q2 related to the termination of certain in-process R&D projects [40] - The company is committed to increasing shareholder value through revenue growth, margin expansion, and free cash flow [33] Q&A Session Summary Question: U.S. Knee growth drivers and market share - Management noted that the company closed the gap to market in the quarter and sees potential for further growth in the knee arena, driven by improved confidence and new product launches [50] Question: Increased confidence for the second half of the year - Management attributed increased confidence to the performance of the knee franchise and the need to maintain focus on S.E.T. [56] Question: Allocation of investments in the back half of the year - Investments will focus on R&D, commercial infrastructure, and specialization in sales organization to drive growth above the weighted average market growth rate [63] Question: Clarification on U.S. Knee growth contributions - Management indicated that while ROSA contributed to growth, the overall strong performance in knees was significant even without it [108] Question: Future performance of the Spine segment - Management expressed confidence in the leadership changes and the potential for positive momentum in the Spine business as new products launch [89]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2019 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 345 East Main Street, Warsaw, IN 46580 (Address of principal e ...

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q1 2019 Results Earnings Conference Call April 26, 2019 8:30 AM ET Company Participants Coleman Lannum - Senior Vice President, Investor Relations Bryan Hanson - President and Chief Executive Officer Daniel Florin - Executive Vice President and Chief Financial Officer Conference Call Participants Robbie Marcus - J.P. Morgan Securities LLC Matthew Taylor - UBS Securities, LLC Pito Chickering - Deutsche Bank Vijay Kumar - Evercore ISI Steven Lichtman - Oppenheimer & Co. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2018 Commission file number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13‑4151777 (State of Incorporation) (IRS Employer Identification No.) 345 East Main Street Warsaw, Indiana 46580 (Address of principal executive offices) (Zip Code) Registrant's telephon ...

Zimmer Biomet Holdings Inc (NYSE:ZBH) Q4 2018 Earnings Conference Call February 1, 2019 8:30 AM ET Company Participants Cole Lannum - Senior Vice President, Investor Relations Bryan Hanson - President & Chief Executive Officer Dan Florin - Chief Financial Officer Conference Call Participants Joanne Wuensch - BMO Capital Markets Mike Matson - Needham & Company Raj Denhoy - Jefferies Bob Hopkins - Bank of America Kyle Rose - Canaccord Richard Newitter - SVB Leerink Glenn Novarro - RBC Capital Markets Matt Mik ...